Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Mex3a Stabilizes INHBB mRNA to Activate Smad Signaling and Promote Hepatocellular Carcinoma Metastasis.

Created on 21 Jul 2026

Authors

Jie-Ru Yang, Zheng-Jie Qu, Fang-Ming Zhou, Jin-E Li, Kai Wang, Yu-Chen Fan

Published in

Annals of surgical oncology. Jul 21, 2026. Epub Jul 21, 2026.

Abstract

Mex3a has been implicated in tumor progression in several malignancies; however, its clinical significance and biological role in hepatocellular carcinoma (HCC) remain incompletely understood.
Mex3a expression patterns and prognostic relevance were first explored using The Cancer Genome Atlas (TCGA) dataset. A single-institution cohort of 59 patients with HCC was then analyzed to evaluate the association between Mex3a expression and clinicopathological characteristics, overall survival (OS), and recurrence-free survival (RFS). Survival outcomes were assessed using Kaplan-Meier analysis and Cox proportional hazards regression. Functional assays in vitro and in vivo were performed to investigate the role of Mex3a in HCC progression.
Mex3a was significantly upregulated in hepatocellular carcinoma tissues compared with non-tumor tissues in the TCGA cohort and was associated with poorer overall survival at the univariate level. In the clinical cohort, high Mex3a expression correlated with aggressive clinicopathological features. Multivariate Cox regression analysis demonstrated that Mex3a expression was an independent prognostic factor for overall survival after adjustment for established clinicopathological variables. In contrast, Mex3a expression was not independently associated with recurrence-free survival. Functional experiments revealed that Mex3a promoted malignant phenotypes of HCC cells in vitro and enhanced tumor progression in vivo.
Mex3a is associated with aggressive tumor behavior and serves as an independent prognostic factor for overall survival, but not recurrence-free survival, in patients with hepatocellular carcinoma. These findings suggest that Mex3a may contribute to disease progression and patient outcomes in HCC.

PMID:
42479360
Bibliographic data and abstract were imported from PubMed on 21 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement